Biotech Firm Telix Pharmaceuticals Pulls US IPO

0
145

Telix did not say whether it plans to consider a future listing in the U.S. Since Telix began planning its IPO at the start of the year, the company said its share price rose from 9.53 Australian dollars to AU$16.46 by market close Wednesday.

“While this is not our desired outcome, Telix’s strategic objectives must align with our duty to existing shareholders,” CEO Christian Behrenbruch said in a statement regarding the cancellation of its U.S. IPO. “I’d like to thank my team for the personal commitment and incredibly long hours put into this IPO process.”

Telix said trading of its Australian shares, which was temporarily halted on Thursday, would resume on Monday.

Signup for the USA Herald exclusive Newsletter